newsfilter
← Latest News
Business Wire·

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Topline data from PORTOLA Phase 2a clinical trial evaluating zetomipzomib in patients with autoimmune hepatitis (AIH) expected in first half 2025 Cash, cash equivalents and marketable securities totaled $148 million